661 results on '"Kuzel, Timothy M."'
Search Results
2. Reduced Bioactive Microbial Products (Pathogen-Associated Molecular Patterns) Contribute to Dysregulated Immune Responses and Impaired Healing in Infected Wounds in Mice with Diabetes
3. Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808
4. CrkII/Abl phosphorylation cascade is critical for NLRC4 inflammasome activity and is blocked by Pseudomonas aeruginosa ExoT
5. Presence of CrkI-containing microvesicles in squamous cell carcinomas could have ramifications on tumor biology and cancer therapeutics
6. Correction: Refining colorectal cancer classification and clinical stratification through a single-cell atlas
7. Refining colorectal cancer classification and clinical stratification through a single-cell atlas
8. IL-10 Dysregulation Underlies Chemokine Insufficiency, Delayed Macrophage Response, and Impaired Healing in Diabetic Wounds
9. Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target
10. Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer
11. The association of phosphodiesterase-5 inhibitors with the biochemical recurrence-free and overall survival of patients with prostate cancer following radical prostatectomy
12. Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer.
13. Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition
14. Renal Cancer
15. Minimum thresholds deemed acceptable by patients and physicians for sensitivity and specificity of mobile skin cancer screening algorithms
16. Sebaceous carcinoma: evidence-based clinical practice guidelines
17. Reduced Bioactive Microbial Products (Pathogen-Associated Molecular Patterns) Contribute to Dysregulated Immune Responses and Impaired Healing in Infected Wounds in Mice with Diabetes
18. Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas
19. Targeting FOXAI-mediated repression of TGF-[beta] signaling suppresses castration-resistant prostate cancer progression
20. Penile cancer: Clinical Practice Guidelines in Oncology.
21. Figure S1, Figure S2, Table S1 from Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib
22. Data from Host miR155 Promotes Tumor Growth through a Myeloid-Derived Suppressor Cell–Dependent Mechanism
23. Supplementary Figures 1-7 from Host miR155 Promotes Tumor Growth through a Myeloid-Derived Suppressor Cell–Dependent Mechanism
24. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
25. Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics
26. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
27. Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805)
28. Contributors
29. T-Cell Lymphomas
30. Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302
31. Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302
32. Minimum sensitivity and specificity of mobile skin cancer screening algorithms
33. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
34. Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
35. National Evaluation of Hospital Performance on the New Commission on Cancer Melanoma Quality Measures
36. Chemotherapy (Primary and Recurrent Disease)
37. Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome
38. The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Non–Clear-Cell Renal Cell Carcinoma: A Case Report and Literature Review
39. Interleukin-2 in the Treatment of Renal Cell Carcinoma and Malignant Melanoma
40. Gut Microbial Shifts Indicate Melanoma Presence and Bacterial Interactions in a Murine Model
41. Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease
42. Radioimmunotherapy of lymphoma
43. Outcome of Patients Treated With a Single-Fraction Dose of Palliative Radiation for Cutaneous T-Cell Lymphoma
44. Additional file 1 of Refining colorectal cancer classification and clinical stratification through a single-cell atlas
45. Novel treatment approaches for cutaneous T-cell lymphoma
46. Overriding impaired FPR chemotaxis signaling in diabetic neutrophil stimulates infection control in murine diabetic wound
47. The association of phosphodiesterase-5 inhibitors with the biochemical recurrence-free and overall survival of patients with prostate cancer following radical prostatectomy
48. Author response: Overriding impaired FPR chemotaxis signaling in diabetic neutrophil stimulates infection control in murine diabetic wound
49. Therapeutic evaluation of immunomodulators in reducing surgical wound infection
50. Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma: Final Results from a Phase I/II Open Label Multi-Center Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.